Grants per year
- 150 - 175 out of 1,104 results
Search results
-
-
Prot #NC-6004-004A: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder Cancer
PPD Investigator Services, LLC, NanoCarrier Co., Ltd.
8/29/17 → 8/29/20
Project: Research project
-
Prot #NU 16H06: A phase l clinical trial evaluating the combination of volasertib (Bl-6727) with vincristine sulfate liposomal injections (VSLI) in adult patients with relapsed/refractory acute lymphoblastic leukemia
National Comprehensive Cancer Network, Boehringer Ingelheim Pharmaceuticals, Inc.
8/24/16 → 8/24/20
Project: Research project
-
Prot #BP39365: An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase IB Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281, in Combination with Atezolizumab ± Bevacizumab, Following Obinutuzumab Pre-Treatment, in Pa
INC Research, LLC, Roche TCRC, Inc.
8/11/17 → 8/11/20
Project: Research project
-
-
Novel safe GR-targeted therapy for hematological malignancies
ILSI Health and Environmental Sciences Institute
1/23/17 → 7/22/20
Project: Research project
-
Prot #CA209-703: NU MRFBC 16M05: A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab Followed
Georgetown University, Bristol-Myers Squibb Company
9/15/17 → 7/14/20
Project: Research project
-
Subproject for Institution # SP0039920
Indiana University-Purdue University Indianapolis, Ovarian Cancer Research Fund Alliance
1/1/17 → 6/30/20
Project: Research project
-
Prot#CA209010: A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Sosman, J. A. & Kuzel, T. M.
6/21/11 → 6/30/20
Project: Research project
-
Epigenetic Vulnerabilities of Ovarian Cancer Stem Cells
Indiana University-Purdue University Indianapolis, Ovarian Cancer Research Fund Alliance
1/1/17 → 6/30/20
Project: Research project
-
Enhancing apoptosis and immunotherapy with CpG coated hollow gold nanoshells for aggressive B cell lymphoma
American Society of Hematology
7/1/19 → 6/30/20
Project: Research project
-
The Role of ZEB1 Mutations in Cutaneous T Cell Lymphoma
Choi, J., Crispino, J. D. & Shilatifard, A.
12/8/15 → 6/30/20
Project: Research project
-
Prot #MEDI4736-NHL-001: A Phase 1/2, Open Label, Multicenter Study To Assess The Safety And Tolerability Of Durvalumab (Anti-PD-L1 Antibody) As Monotherapy And In Combination Therapy In Subjects With Lymphoma Or Chronic Lymphocytic Leukemia
ICON plc, Celgene International II Sàrl
6/30/17 → 6/30/20
Project: Research project
-
Prot #KCP-330-008: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients = 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are
Frankfurt, O.
5/14/14 → 5/14/20
Project: Research project
-
NU UW16B13: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
Cristofanilli, M.
Washington University St. Louis, Puma Biotechnology, Inc.
5/1/17 → 5/1/20
Project: Research project
-
-
Prot #BO29337: A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison with BR Alone or GDC-0199 Plus Rituximab (R) in Patients with Relapsed and Refractory Follicular Non-H
Pro, B.
4/10/15 → 4/30/20
Project: Research project
-
Reversing primary anti-PD-1 resistance with ipilimumab and nivolumab
University of California at Los Angeles, American Association for Cancer Research
5/1/17 → 4/30/20
Project: Research project
-
Prot #D081DC00007: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment w
Covance Inc., AstraZeneca Pharmaceuticals LP
4/7/17 → 4/7/20
Project: Research project
-
Prot #NU HM16B03: Neoadjuvant Phase II Study of Everolimus Plus Cisplatin in Triple Negative Breast Cancer Patients with Residual Disease After Standard Chemotherapy
Cristofanilli, M.
Methodist Hospital Research Institute, Novartis Pharmaceuticals Corporation
3/30/17 → 3/30/20
Project: Research project
-
Prot #CX-839-003: A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia
Frankfurt, O.
SCRI Development Innovations, LLC, Calithera Biosciences, Inc.
3/19/14 → 3/19/20
Project: Research project
-
Prot #CA-170-101: A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas
INC Research, LLC, Curis, Inc.
3/14/17 → 3/14/20
Project: Research project